Success Metrics

Clinical Success Rate
84.6%

Based on 11 completed trials

Completion Rate
85%(11/13)
Active Trials
0(0%)
Results Posted
109%(12 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_2
7
50%
Ph phase_3
1
7%
Ph phase_1
5
36%

Phase Distribution

5

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
7(53.8%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(11)
Terminated(2)
Other(1)

Detailed Status

Completed11
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
84.6%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (38.5%)
Phase 27 (53.8%)
Phase 31 (7.7%)

Trials by Status

unknown17%
completed1179%
terminated214%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_1

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

NCT02520063
completedphase_1

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

NCT02429843
unknown

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NCT02354612
completedphase_2

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324
completedphase_3

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

NCT02979899
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT02520063Phase 1

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Completed
NCT02429843Phase 1

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Completed
NCT02354612

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Unknown
NCT03418324Phase 2

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Completed
NCT02979899Phase 3

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

Completed
NCT03780010Phase 1

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

Completed
NCT02664961Phase 2

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Terminated
NCT01564914Phase 2

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

Completed
NCT02396511Phase 2

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Completed
NCT01326481Phase 1

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Completed
NCT01090765Phase 1

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Completed
NCT01375569Phase 2

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Completed
NCT01328574Phase 2

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Completed
NCT01778530Phase 2

TRC105 for Recurrent Glioblastoma

Terminated

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14